partnering with the big end of town comes with pros and cons. aspen pharma are only paying 400k for milestone payments and the royalty is 10% of NET sales. RX5 is not shooting out the lights, the share price has only gone backwards since the deal was announced. we will only get a big share price boost if there is a US commercial partnership for RX5 on suitable terms, who knows how far away that is when the phase3 trial completion has been pushed back until some date not even the company itself knows
partnering with the big end of town comes with pros and cons....
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
